BiotechTube
Circurna

Circurna

Cambridge, United States· Est.
circurna.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

Circurna is a private, pre-clinical biotech leveraging a proprietary circular RNA (ciRNA™) platform to develop next-generation therapeutics. The platform is engineered to enable sustained protein expression, improved tolerability, room-temperature stable formulations, and flexible delivery methods like microneedle patches. With a pipeline spanning oncology, fibrosis, autoimmune, and infectious diseases, Circurna is positioning itself to address core limitations of first-generation RNA technologies and expand the reach of RNA medicine.

OncologyFibrosisAutoimmune DiseasesInfectious DiseasesChronic Conditions

Technology Platform

Proprietary ciRNA™ circular RNA platform designed for sustained protein expression, improved tolerability, room-temperature stable LNP formulations, and flexible delivery (e.g., microneedle patches).

Funding History

1
Total raised:$50M
Series A$50M

Opportunities

Circurna's technology addresses major limitations of first-generation mRNA, creating opportunities in chronic disease treatment (requiring sustained expression), global vaccine access (via thermostable formulations), and patient-centric care (via needle-free patches).
The proven success of the RNA modality provides a large and receptive market for improved versions.

Risk Factors

Key risks include the unproven clinical efficacy and safety of circular RNA therapeutics, the significant technical challenges of manufacturing and delivery, intense competition in next-generation RNA, and the substantial capital required to advance from pre-clinical to clinical stages.

Competitive Landscape

Circurna competes in the rapidly evolving next-generation RNA therapeutics space against companies developing self-amplifying RNA, modified nucleosides, and other circular RNA platforms. It must differentiate on a combination of durability, tolerability, formulation stability, and delivery innovation to capture market share.

More companies in RNA Therapeutics (non-mRNA) →More companies in United States →